News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Pfizer Patent Cliff
$17B
Big Pharma & Biotech
Pfizer Stock Price
$26.3
Big Pharma & Biotech
CellCentric Funding
$220M
Healthcare M&A & Funding
Key driverPfizer confronts major patent cliff while beating Q1 estimates; M&A and pipeline expansion continue across Big Pharma
Daily briefHealthcare· Money365.Market AI ·

Pfizer Faces $17B Patent Cliff; Merck Expands CML Pipeline

Big Pharma navigates patent pressures while M&A activity heats up; UnitedHealth eases prior authorization requirements

Big Pharma & Biotech

Neutral
PFEMRK
Pfizer ($PFE) topped first-quarter sales expectations and reaffirmed 2026 guidance, but faces mounting pressure from a $17 billion patent cliff that threatens future growth beyond its Covid product portfolio. The company received FDA approval for VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy for ER+/HER2-, ESR1-mutated advanced breast cancer, co-developed with Arvinas.
$PFE also reported positive Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, strengthening its oncology pipeline as the stock trades around $26.3. Meanwhile, Merck ($MRK) concluded its acquisition of Terns to expand its chronic myeloid leukemia pipeline, with the FDA granting breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the T315I mutation.

Healthcare M&A & Funding

Neutral

Gilead EPS Growth

52%+52%
GILD
Privately held biotech firm CellCentric raised $220 million in a funding round led by specialist investor Venrock to advance development of its experimental drug for blood cancer. The substantial financing round highlights continued investor appetite for oncology-focused biotechs despite broader market headwinds. In a separate development, Gilead Sciences ($GILD) saw its earnings per share expected to rise 52% as state AIDS drug programs face challenges, according to the AIDS Healthcare Foundation.
Arcus Biosciences ended its Phase 3 STAR-121 lung cancer trial after a futility analysis indicated the study was unlikely to meet its goals, with $GILD deciding not to continue its broad option rights within their collaboration.

Health Insurance & Managed Care

Bullish
UNH
UnitedHealth Group ($UNH) plans to remove prior authorization requirements for a large share of healthcare services starting in 2026, a policy shift intended to cut administrative complexity while improving access and affordability for patients and providers. The change affects core insurance operations and could influence how hospitals, physicians, and patients interact with $UNH plans, representing a significant operational adjustment for the nation's largest health insurer.
UnitedHealth came roaring back in April, with the insurer and healthcare giant getting back to a solid profit footing after earlier challenges.

MedTech & Diagnostics

Bullish

Tempus AI Q1 Revenue

$348.1M+36%

SOPHiA GENETICS Q1 Revenue

$21.7M+22%
Tempus AI reported first-quarter 2026 revenue of $348.1 million, up 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook.
SOPHiA GENETICS reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Both companies demonstrated strong momentum in the precision medicine and genomic diagnostics space, reflecting growing adoption of AI-powered healthcare analytics platforms.

FDA & Regulatory Updates

Neutral
MRKPFE
The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the T315I mutation, supporting Merck's ($MRK) recently completed Terns acquisition. The California Supreme Court is considering whether manufacturers of drugs that are considered safe are legally obligated to continue developing drugs that are allegedly safer, a case that could establish a potential "duty to innovate" for pharmaceutical companies.
Pfizer ($PFE) received FDA approval for VEPPANU, marking the first PROTAC protein degrader therapy to reach the market for ER+/HER2-, ESR1-mutated advanced breast cancer.

Looking Ahead

Neutral
BMYABT
Bristol Myers Squibb ($BMY) announced it will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026, participating in a fireside chat. The California Supreme Court's deliberation on pharmaceutical "duty to innovate" could set important precedent for drug development obligations across the industry.
Abbott Laboratories ($ABT) stock is trading near 52-week lows, though insiders are purchasing shares of the blue-chip dividend payer, signaling confidence in the company's long-term business and dividend story.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy